🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Dizal Pharmaceuticals clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China and USA registers with Dizal Pharmaceuticals as lead sponsor. Synced 26 Sep 2026
18Current trials
14Recruiting now
19Drugs in these trials
2Trial registers
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Dizal Pharmaceuticals is the lead sponsor of 18 current clinical trials in our China and USA registers. 14 are recruiting patients now. The most common phase is Phase 1/2. The drugs named most often in its trials are Birelentinib, Sunvozertinib and Carboplatin. The most-studied condition is Non-Small Cell Lung Cancer.

ClinicalTrials.gov trials by status

  • Recruiting1478%
  • Not yet open16%
  • Active, closed317%

Trials by phase

  • Phase 1/2633%
  • Phase 2633%
  • Phase 3317%
  • Phase 1211%
  • Phase 2/316%
01

Clinical trials sponsored by Dizal Pharmaceuticals

18 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)
NCT07154264 · ClinicalTrials.gov ↗ · Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Phase 2 Recruiting 2025-09 China
A Phase 1/2 Study of GW5282 in Participants With Advanced Solid Tumors
NCT07328217 · ClinicalTrials.gov ↗ · Advanced Solid Tumors
Drug: GW5282
Phase 1/2 Recruiting 2026-01 China
DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7)
NCT07070440 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer
Phase 1/2 Recruiting 2025-07 China
A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1)
NCT06905197 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer
Phase 1 Recruiting 2025-05 USA
DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29)
NCT06276283 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer
Phase 2 Recruiting 2023-02 China
Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN2)
NCT06813365 · ClinicalTrials.gov ↗ · Nonsmall-cell Lung Cancer
Phase 1 Recruiting 2024-06 China
DZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8)
NCT06539182 · ClinicalTrials.gov ↗ · Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Phase 2 Recruiting 2024-04 China
Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)
NCT07079475 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer
Phase 1/2 Recruiting 2025-07 China
A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)
NCT07139873 · ClinicalTrials.gov ↗ · Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Phase 3 Recruiting 2025-09 China
DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)
NCT07059650 · ClinicalTrials.gov ↗ · Diffuse Large B-Cell Lymphoma
Phase 1/2 Recruiting 2025-08 China
A Phase II Clinical Trial of DZD9008 in Combination With AZD4205 in Standard Treatment Failed NSCLC Patients With EGFR Mutations (WU-KONG21)
NCT06295432 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer
Phase 2 Recruiting 2023-06 China
A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)
NCT07234162 · ClinicalTrials.gov ↗ · Peripheral T-cell Lymphoma
Phase 3 Recruiting 2024-05 China
A Study of DZD8586 in Adults With Primary Immune Thrombocytopenia (ITP) (TAI-SHAN11)
NCT07294365 · ClinicalTrials.gov ↗ · Immune Thrombocytopenia (ITP)
Phase 2 Recruiting 2026-01 China
Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3)
NCT07496229 · ClinicalTrials.gov ↗ · T-cell Lymphomas
Phase 1/2 Recruiting 2026-04 China
Birelentinib Plus R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (TAI-SHAN19)
NCT07712588 · ClinicalTrials.gov ↗ · Diffuse Large B-Cell Lymphoma (DLBCL)
Phase 2/3 Not yet open 2026-09 China
Sunvozertinib (DZD9008) in Pretreated Lung Cancer Patients with EGFR Exon20 Insertion Mutation (WU-KONG6)
NCT05712902 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer
Phase 2 Active, closed 2021-07 China
Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)
NCT03974022 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer
Phase 1/2 Active, closed 2019-07 USA, China
A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)
NCT05668988 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer
Phase 3 Active, closed 2022-12 USA, China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Dizal Pharmaceuticals trials

19 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Dizal Pharmaceuticals trials

11 conditions
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China1713
Clinical trials in USA31

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Non-Small Cell Lung Cancer

SponsorTrials
Sichuan Baili Pharmaceutical15
AstraZeneca13
Merck Sharp & Dohme9
Hoffmann-La Roche7
Daiichi Sankyo5
Hunan Province Tumor Hospital5
Shanghai Pulmonary Hospital, Shanghai, China4
Shanghai Chest Hospital4
BioNTech3
Jiangsu Hansoh Pharmaceutical3

Sponsors with the most current trials registered for this condition.

06

Questions about Dizal Pharmaceuticals trials

How many clinical trials does Dizal Pharmaceuticals sponsor?

Dizal Pharmaceuticals is the lead sponsor of 18 current trials on ClinicalTrials.gov in our China and USA registers, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Dizal Pharmaceuticals trials recruiting?

Yes. 14 of its 18 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Dizal Pharmaceuticals testing?

Its current trials name 19 drugs and biologicals as interventions. The most frequent are Birelentinib (6), Sunvozertinib (6), Carboplatin (2), DZD6008 (2) and GW5282 (2). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.